HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Palliative Care20 papers

Primary astroblastoma of brain

Last edited: 4/15/2026

Overview

Primary astroblastoma is a rare, slow-growing neoplasm that arises from astroblasts in the brain, typically presenting with focal neurological deficits and often located in the supratentorial region 1.

Diagnosis

  • Neurological examination and imaging (MRI) are essential for initial assessment 1.
  • Contrast-enhanced MRI helps in delineating tumor characteristics and extent 1.
  • Histopathological examination with immunohistochemistry is definitive for diagnosis, distinguishing astroblastoma from other glial tumors 1.
  • Grading systems for astroblastomas are not well-established; typically, they are considered low-grade based on histological features 1.

    • Management

  • Surgical resection is the primary treatment, aiming for maximal safe tumor removal 1.
  • Adjuvant radiotherapy may be considered for residual or recurrent disease, though evidence is limited 1.
  • Chemotherapy is generally not indicated for primary astroblastomas, except in specific cases of aggressive behavior 1.
  • Supportive care and symptom management are crucial, tailored to individual patient needs 1.

    • Special Populations

  • No specific guidance provided for pregnancy, pediatrics, elderly, or comorbidities in the given abstracts 1.

    • Key Recommendations

  • Perform contrast-enhanced MRI for definitive diagnosis and assessment of primary astroblastoma 1.
  • Prioritize maximal safe surgical resection as the mainstay of treatment 1.
  • Consider adjuvant radiotherapy for residual or recurrent disease on a case-by-case basis due to limited evidence 1 (Evidence: Moderate).

    • References

    1 Bartlett J, Freshwater E. Drug level monitoring in palliative patients. BMJ supportive & palliative care 2021. link

    Original source

    1. [1]
      Drug level monitoring in palliative patients. — Bartlett J, Freshwater E BMJ supportive & palliative care (2021)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG